Abstract:
Objective
To analyze the effect of montelukast combined with tanshinone on children with Henoch Schonlein purpura and its influence on serum inflammatory factors.
Methods
A total of 117 children with Henoch Schonlein purpura treated from January 2015 to February 2016 in Qi County Maternal and Child Health Planning and Child Care Service Center of Henan Province were selected as the study subjects, and they were randomly divided into the control group(58 cases) and observation group(59 cases). Both groups were treated with montelukast, and the observation group was given tanshinone intravenous drip, with 30 d as 1 course. The clinical efficacy, the improvement of serum inflammatory factors(interleukin 4, 6 and tumor necrosis factor alpha) and the incidence of adverse reactions were observed in both groups.
Results
The total effective rate of the observation group after treatment was 96.6%(57/59), which was significantly higher than that of the control group(82.8%,48/58), the difference being statistically significant(P<0.05). The levels of interleukin 4, 6 and TNF-alpha in both groups were significantly lower than those before treatment, and the difference was statistically significant(P<0.05). After treatment of 30d, the levels of interleukin 4, 6 and tumor necrosis factor alpha in the observation group were significantly lower than those in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the 2 groups during the treatment period(P>0.05).
Conclusion
Montelukast combined with tanshinone can significantly improve the level of serum inflammatory factors in children with Henoch Schonlein purpura and the efficacy of treatment and it is safe.

Key words: Henoch Schonlein purpur, Montelukast, Tanshinone, Serum inflammatory factors, Children